| Literature DB >> 35122204 |
Mariana Luz1,2,3, Bruna Brandão Barreto4,5, Roberta Esteves Vieira de Castro6, Jorge Salluh7,8, Felipe Dal-Pizzol9, Caio Araujo10, Audrey De Jong11, Gérald Chanques11, Sheila Nainan Myatra12, Eduardo Tobar13, Carolina Gimenez-Esparza Vich14, Federico Carini15, Eugene Wesley Ely16,17,18,19,20, Joanna L Stollings20,21, Kelly Drumright22, John Kress23, Pedro Povoa24,25,26, Yahya Shehabi27, Wilson Mphandi28, Dimitri Gusmao-Flores4,5.
Abstract
BACKGROUND: Since the publication of the 2018 Clinical Guidelines about sedation, analgesia, delirium, mobilization, and sleep deprivation in critically ill patients, no evaluation and adequacy assessment of these recommendations were studied in an international context. This survey aimed to investigate these current practices and if the COVID-19 pandemic has changed them.Entities:
Keywords: Analgesia; COVID-19; Delirium; Mobilization; Sedation; Sleep deprivation
Year: 2022 PMID: 35122204 PMCID: PMC8815719 DOI: 10.1186/s13613-022-00985-y
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 10.318
Survey respondent demographics and their main practical setting characteristics
| Variables | Measures before the COVID-19 pandemic | Measures during the COVID-19 pandemic |
|---|---|---|
| Age | 41.86 (22.2)a | 41.9 (10)a |
| Years of practice | 12.5 (5–19)b | 9 (5–20)b |
| Critical care medicine specialist— | 1126 (76.3) | 216 (74.0) |
| Years of specialty in critical care medicine | 8 (3–17)b | 9 (4–11)b |
aMean (standard deviation); bmedian (interquartile ratio); cICU, intensive care unit; dp < 0.001
Fig. 1Analgesia practices before the COVID-19 pandemic. a Drugs for pain management; b nonpharmacologic strategies for pain management; c tools for pain assessment in patients able to communicate; d tools for pain assessment in patients unable to communicate
Fig. 2Sedation practices in different clinical settings before the COVID-19 pandemic. a Drugs usually used for sedation in patients under MV; b drugs used for sedation in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) [25]; c drugs used for sedation in patients with septic shock; d drugs used for sedation in patients under noninvasive MV
Sedation choices by continent before the COVID-19 pandemic
| Variables | Asia | Europe | South America |
|---|---|---|---|
| Drugs usually used for sedation | |||
| | |||
| Lorazepama | 10.1 | 4.4 | 16.6 |
| Haloperidolb | 20.7 | 20.3 | 28.3 |
| Morphinea | 45.6 | 17.2 | 17.6 |
| Fentanyla | 77.5 | 19.1 | 53.6 |
| Remifentanila | 0.6 | 27.9 | 6.1 |
| Dexmedetomidinea | 64.5 | 61.00 | 67.9 |
| Ketaminea | 5.9 | 25.7 | 34.2 |
| Quetiapinea | 14.2 | 8.3 | 29.2 |
| Sedative drugs used for sedation in patients with septic shock | |||
| | |||
| Lorazepam | 3 | 0.7 | 2.7 |
| Haloperidolb | 4.1 | 0.7 | 3.9 |
| Morphinea | 32.5 | 11.8 | 7 |
| Fentanyla | 79.9 | 25 | 66.1 |
| | |||
| Remifentanila | 0.59 | 20.3 | 10.2 |
| Dexmedetomidinea | 20.1 | 12 | 30.9 |
| Ketaminea | 8.3 | 16.2 | 32 |
| Quetiapineb | 2.4 | 0.3 | 4.2 |
| Sedative drugs used for sedation in patients with ARDS | |||
| | |||
| Lorazepamb | 0.6 | 0.3 | 4 |
| Haloperidol | 2.4 | 1 | 3 |
| Morphinea | 39 | 14.5 | 10 |
| | |||
| Propofola | 22.5 | 67.2 | 65.6 |
| Remifentanila | 0 | 21.6 | 10.26 |
| Dexmedetomidinea | 35.5 | 11.8 | 26.1 |
| Ketaminea | 2.4 | 16.4 | 30.9 |
| Quetiapine | 3.6 | 0.5 | 3.9 |
| Sedative drugs used for sedation in agitated patients under noninvasive ventilation | |||
| Midazolamb | 20.1 | 13.7 | 8.9 |
| Lorazepam | 5.3 | 5.9 | 8.1 |
| | |||
| Morphineb | 13.6 | 14.5 | 23.7 |
| Fentanyla | 32 | 6.1 | 14.9 |
| Propofola | 3 | 25.5 | 10.8 |
| Remifentanila | 1.8 | 9.6 | 3.7 |
| | |||
| Ketaminea | 0.6 | 7.4 | 16.6 |
| Quetiapinea | 13 | 10.3 | 31.7 |
a p < 0.001; bp < 0.05; cARDS, acute respiratory distress syndrome
Italic emphasis are the most frequent choice in each context
Fig. 3Physicians’ opinions about strategies for improving ICU sedation practices stratified by continents